| 引用本文: |
马爱霞,张籍元,钱焊森,等.医保支付价背景下药物经济学评价的应用探索[J].中国卫生经济,2018,(2):74-76.[点击复制] |
.Application of Drug Economics Evaluation in the Background of Medical Insurance Payment[J].CHINESE HEALTH ECONOMICS,2018,(2):74-76.[点击复制] |
|
| 摘要: |
| 自 2015 年绝大部分药品取消政府定价以来，医保支付价制度成为管控药品价格的重要手段。当前，虽然各省市已逐步出台和实施医保支付价相关政策，但在实施中仍存在一些问题，一方面，各省制定“医保支付价”时仅按通用名分组，将最低中标价作为医保支付价，由于我国部分仿制药与原研药质量相差较大，如此将引发 “劣药驱逐良药”的现象。另一方面，虽然医保部门已鼓励企业在谈判定价中提交经济学评价证据，但其具体评价流程仍有待规范。针对上述两方面的问题，本文通过借鉴国外经验，为我国医保支付价制定及经济学评价流程的规范提出合理建议。 |
| 关键词: |
| DOI： |
|
| 基金项目: |
|
| Application of Drug Economics Evaluation in the Background of Medical Insurance Payment |
|
| () |
| Abstract: |
| Since the abolition of government pricing in most of the drugs in 2015, the basis price of medical insurance payment has become an important means of controlling drug prices. At present, although some provinces have gradually implemented this policy , but there are still some problems in the implementation, on the one hand, grouping only by generic name and the basis price is the lowest tender price, thus will lead to "bad medicine to drive good medicine" due to the quality difference between the generic drugs and the original drug s .On the other hand, although the medical insurance department has encouraged enterprises to submit evidence of economic evaluation in negotiated pricing, the evaluation process is still to be standardized. In view of the above two aspects, this paper use abroad experience for reference and makes reasonable suggestions for the basis price and evaluation process in our country |
| Key words: |
